The assignee ranking in this dataset covers 100 companies, with the leader holding 187 records and the fifth-placed holder at 57. The top five assignees combined account for 28.5% of all 1,722 records in scope, and the top ten reach 42.0%, so the field has a clear concentration at the top alongside a long tail of single- or few-filing entrants. This is a families-and-records view, so it is a fairer read of true filing weight than raw document counts alone.

Filings peaked at 95 in 2019 and then declined, with the complete data showing 53 filings in 2021 falling to 19 in 2024, a -64% drop over that three-year window. Because publication typically lags filing by around 18 months, the years closest to the 2026 data cut-off are undercounted and should not be treated as evidence of a continuing slowdown on their own. Read the 2021-2024 window as the most reliable recent signal available in this corpus.

Nearly all records, 99.7% of the 1,722 in scope, sit in C12N, covering microorganisms and genetic engineering methods, which includes most media, culture-condition and cell-line claims. A61K (medicinal preparations) follows at 25.8%, reflecting therapeutic-use framing layered on top of culture methods. Bioreactor and apparatus claims (C12M) and analytical/testing claims (G01N) are each much smaller at 5.2%, meaning the physical scale-up hardware and process-monitoring space is comparatively under-claimed relative to the biology and media chemistry.